New combo aims to boost transplant success in rare blood cancers

NCT ID NCT04282187

Recruiting now Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times

Summary

This study tests whether giving a chemotherapy drug (decitabine) along with a JAK inhibitor (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPNs) get to transplant and have better outcomes. About 25 adults with MPN that has progressed to a more aggressive phase will take part. The goal is to see if this combination is better than standard chemotherapy at preparing patients for transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ACUTE MYELOID LEUKEMIA ESSENTIAL THROMBOCYTHEMIA MYELODYSPLASTIC SYNDROME MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM MYELOPROLIFERATIVE NEOPLASM MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED POLYCYTHEMIA VERA PRIMARY MYELOFIBROSIS SECONDARY MYELOFIBROSIS